Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2009 Aug;31(8):561–570. doi: 10.1097/MPH.0b013e3181a6e043

Table 1.

Inhibition of ASPS Tumor Growth by Cytotoxic and Anti-Angiogenic Therapy

Max Mean % Weight loss Optimal %T/C median days to 600 mg %growth delay net log cell kill
vehicle control Q3D×6 7.7 NA 94 NA NA
100 μg bevacizumab Q3D×6 5.4 27 >119 27 0.1
12 mg topotecan/kg Q4D×4 9.7 36 >114 21 0.1
1 mg topotecan/kg QD×15 14.6 34 122 30 0.2
100 μg bevacizumab Q3D×6 + 1 mg topotecan/kg QD×15 7.9 26 159 70 0.7